临床试验数据集规范的必要性,以支持临床药理学对免疫性进行审查
Sophie Shubow1,2, Mohsen Rajabi Abhari3,4, Anh Ta3,5
1Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. Sophie.Shubow@fda.hhs.gov.
The AAPS journal
|February 24, 2026
概括
评估抗药抗体 (ADA) 反应对于生物许可申请 (BLA) 至关重要. 许多BLA面临数据集问题,推迟审查. 针对免疫性数据的标准化规范可以提高监管效率.
科学领域:
- 临床药理学 临床药理学
- 监管科学 监管科学
- 生物学的发展 生物学的发展
背景情况:
- 产品免疫性评估,特别是抗药抗体 (ADA) 反应,对于生物许可申请 (BLA) 是至关重要的.
- 临床药理学审查侧重于ADA对药理动力学 (PK) 的影响,使用特定分析数据集 (ADSL,ADPC,ADIS).
- 缺少从SDTM IS域中导出ADIS数据集的指导,导致BLA数据质量的变化.
研究的目的:
- 分析向FDA的药物评估和研究中心 (CDER) 提交的BLA中的ADIS,ADPC和ADSL数据集的可用性和内容.
- 确定影响免疫性数据临床药理学审查效率的共同数据集问题.
主要方法:
- 审查了在2019年至2022年期间提交给CDER的48个BLA.
- 评估ADSL,ADPC和ADIS数据集的可用性和内容.
- 分类数据集问题,包括数据报告和结构问题.
主要成果:
- 75%的BLA展示了至少一个数据集问题.
- 50%的人有数据报告问题 (格式/缺失数据),17%的人有数据结构问题.
- 8%的BLA提出了多种类型的数据集问题.
结论:
- 在BLA中存在重要的数据集问题,阻碍了对免疫性数据的有效监管审查.
- 建议公布明确的临床试验数据集规范.
- 标准化的规范将提高CDER对BLA临床药理学审查的效率.
相关概念视频
Clinical Trials
10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.9K
Clinical Trials: Overview
5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Clinically Relevant Drug Product Specifications: Methods of Establishment
274
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
274
Preclinical Development: Overview
6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K
Bioavailability Study Design: Healthy Subjects Versus Patients
190
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
190
Bioequivalence studies: Biowaivers
329
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
329


